JP2016513097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513097A5 JP2016513097A5 JP2015556938A JP2015556938A JP2016513097A5 JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5 JP 2015556938 A JP2015556938 A JP 2015556938A JP 2015556938 A JP2015556938 A JP 2015556938A JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- albumin
- composition according
- paclitaxel
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 102000009027 Albumins Human genes 0.000 claims description 16
- 108010088751 Albumins Proteins 0.000 claims description 16
- 229930012538 Paclitaxel Natural products 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 8
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 238000009094 second-line therapy Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 21
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763391P | 2013-02-11 | 2013-02-11 | |
| US61/763,391 | 2013-02-11 | ||
| US13/791,841 US9149455B2 (en) | 2012-11-09 | 2013-03-08 | Methods of treating melanoma |
| US13/791,841 | 2013-03-08 | ||
| PCT/US2013/072877 WO2014123612A1 (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214523A Division JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513097A JP2016513097A (ja) | 2016-05-12 |
| JP2016513097A5 true JP2016513097A5 (enExample) | 2017-01-12 |
| JP6388880B2 JP6388880B2 (ja) | 2018-09-12 |
Family
ID=51300036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556938A Active JP6388880B2 (ja) | 2013-02-11 | 2013-12-03 | メラノーマの治療方法 |
| JP2017214523A Active JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
| JP2019006038A Withdrawn JP2019056014A (ja) | 2013-02-11 | 2019-01-17 | メラノーマの治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214523A Active JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
| JP2019006038A Withdrawn JP2019056014A (ja) | 2013-02-11 | 2019-01-17 | メラノーマの治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2953622B1 (enExample) |
| JP (3) | JP6388880B2 (enExample) |
| KR (1) | KR102148551B1 (enExample) |
| CN (2) | CN105120859B (enExample) |
| BR (1) | BR112015019064A8 (enExample) |
| CA (1) | CA2900668A1 (enExample) |
| ES (1) | ES2872328T3 (enExample) |
| HK (1) | HK1218506A1 (enExample) |
| IL (1) | IL240388B (enExample) |
| MX (1) | MX377729B (enExample) |
| NZ (1) | NZ630239A (enExample) |
| WO (1) | WO2014123612A1 (enExample) |
| ZA (1) | ZA201505956B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| ES2763318T3 (es) * | 2014-10-06 | 2020-05-28 | Mayo Found Medical Education & Res | Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| MX2019002474A (es) * | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| WO2012048223A1 (en) * | 2010-10-08 | 2012-04-12 | Abraxis Bioscience, Llc | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer |
-
2013
- 2013-12-03 EP EP13874757.1A patent/EP2953622B1/en active Active
- 2013-12-03 ES ES13874757T patent/ES2872328T3/es active Active
- 2013-12-03 BR BR112015019064A patent/BR112015019064A8/pt not_active Application Discontinuation
- 2013-12-03 CN CN201380075292.9A patent/CN105120859B/zh active Active
- 2013-12-03 MX MX2015010312A patent/MX377729B/es active IP Right Grant
- 2013-12-03 WO PCT/US2013/072877 patent/WO2014123612A1/en not_active Ceased
- 2013-12-03 JP JP2015556938A patent/JP6388880B2/ja active Active
- 2013-12-03 KR KR1020157024822A patent/KR102148551B1/ko active Active
- 2013-12-03 CA CA2900668A patent/CA2900668A1/en not_active Abandoned
- 2013-12-03 NZ NZ630239A patent/NZ630239A/en unknown
- 2013-12-03 HK HK16106468.2A patent/HK1218506A1/zh unknown
- 2013-12-03 CN CN201811025229.5A patent/CN109200031A/zh active Pending
-
2015
- 2015-08-06 IL IL240388A patent/IL240388B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05956A patent/ZA201505956B/en unknown
-
2017
- 2017-11-07 JP JP2017214523A patent/JP6470381B2/ja active Active
-
2019
- 2019-01-17 JP JP2019006038A patent/JP2019056014A/ja not_active Withdrawn